Consistent with our previous observations with MCC950, mice treated with ADS032 from day 3 post‐challenge display delayed or reduced weight loss (Figure 8a, red triangles) and significantly reduced mortality (Figure 8b, red dotted line), highlighting that targeting NLRP3 protects against detrimental inflammation late in infection. Here, NLRP3 is linked to infection.